GenMark Diagnostics (NASDAQ:GNMK) has filed an application with the FDA seeking emergency use authorization for its eSensor SARS-CoV-2 Test, a molecular assay that detects the presence of the coronavirus.
The test is performed on the company’s multiplex molecular diagnostic system called the XT-8 that can generate results from 96 samples in five hours.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.